First set of recommendations advocating for the holistic care of people living with hattr amyloidosis developed by international panel of patient advocates and healthcare professionals

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced the first-ever recommendations for patient- and family-centred holistic care for people living with hereditary transthyretin-mediated amyloidosis, also known as hattr or attrv*. the recommendations, published in the bmj open,1 were developed by an expert panel of patient advocates and healthcare professionals (hcps), the primary consensus panel, and endorsed by.
ALNY Ratings Summary
ALNY Quant Ranking